Prasad Bhanu, Giebel Shelley, Garcia Francisco, Goyal Kunal, Shrivastava Pratima, Berry Warren
Section of Nephrology, Regina General Hospital, Department of Medicine, Regina, Saskatchewan, Canada.
Faculty of Nursing, Research and Innovation Centre, University of Regina, Regina, Saskatchewan, Canada.
Kidney Int Rep. 2018 Feb 2;3(3):638-644. doi: 10.1016/j.ekir.2018.01.006. eCollection 2018 May.
Loin pain hematuria syndrome (LPHS) is characterized by severe unilateral or bilateral loin pain that suggests a renal origin but occurs in the absence of identifiable or relevant urinary tract disease. Hematuria can either be microscopic or macroscopic, but the renal abnormalities responsible for the hematuria are unexplained. Debilitating pain refractory to conventional pain medications is the main cause of morbidity.
We conducted a single-arm, single-center study. Twelve patients between the ages of 21 and 62 years (11 female, 1 male) with LPHS underwent endovascular ablation of the renal nerves between July 2015 and November 2016, using the Vessix renal denervation system. The primary objective was to achieve 30% reduction in self-reported pain with the McGill Pain Questionnaire (MPQ) at 6 months. The secondary objectives were to measure changes in disability (Oswestry Disability Index [ODI]), mood (Geriatric Depression Scale [GDS]), and quality of life (EuroQol-5D [EQ-5D] and the MOS 36-Item Short Form Survey [SF-36]) scores from baseline to 6 months postprocedure.
Ten of 12 patients at 3 months and 11 of 12 patients at 6 months reported a >30% reduction in pain based on the MPQ at 3 and 6 months. We found consistent improvements in MPQ, ODI, GDS, EQ-5D, and SF-36 scores from baseline to 6 months postprocedure.
We conclude that renal denervation is associated with a considerable improvement in pain, disability, quality of life, and mood. Our results suggest that percutaneous catheter-based delivery of radiofrequency energy is a safe, rapid treatment option that should be considered in all patients with LPHS.
腰背痛血尿综合征(LPHS)的特征是严重的单侧或双侧腰背痛,提示疼痛源于肾脏,但在没有可识别的或相关的泌尿系统疾病的情况下发生。血尿可以是镜下血尿或肉眼血尿,但导致血尿的肾脏异常原因不明。常规止痛药物难以缓解的使人衰弱的疼痛是发病的主要原因。
我们进行了一项单臂、单中心研究。2015年7月至2016年11月期间,12名年龄在21至62岁之间的LPHS患者(11名女性,1名男性)使用Vessix肾去神经支配系统接受了肾神经血管内消融术。主要目标是在6个月时通过麦吉尔疼痛问卷(MPQ)使自我报告的疼痛减轻30%。次要目标是测量从基线到术后6个月残疾程度(奥斯威斯残疾指数[ODI])、情绪(老年抑郁量表[GDS])和生活质量(欧洲五维健康量表[EQ-5D]和医学结局研究简明健康调查36项量表[SF-36])评分的变化。
12名患者中有10名在3个月时以及12名患者中有11名在6个月时报告,根据3个月和6个月时的MPQ,疼痛减轻超过30%。我们发现从基线到术后6个月,MPQ、ODI、GDS、EQ-5D和SF-36评分持续改善。
我们得出结论,肾去神经支配与疼痛、残疾、生活质量和情绪的显著改善相关。我们的结果表明,基于经皮导管的射频能量传递是一种安全、快速的治疗选择,所有LPHS患者都应考虑采用。